Atorvastatin and rosuvastatin are not the same medication. They belong to the same drug class (statins) and both lower LDL cholesterol, but they differ in potency, how your body processes them, which other medications they interact with, and how they’re dosed. Rosuvastatin is the more potent of the two, meaning lower doses achieve similar cholesterol reductions.
How Their Potency Compares
Rosuvastatin lowers LDL cholesterol more per milligram than atorvastatin. Across their full dose ranges, rosuvastatin reduces LDL by roughly 47% to 62%, while atorvastatin reduces it by about 38% to 54%. That gap matters most when you look at dose equivalents: rosuvastatin 5 mg produces roughly the same LDL reduction (36% to 40%) as atorvastatin 20 mg. Rosuvastatin 10 mg matches what takes 40 mg or more of atorvastatin.
Here’s a simplified comparison based on UCSF Hospital data:
- 31% to 35% LDL reduction: Atorvastatin 10 mg (no rosuvastatin equivalent needed at this low a target)
- 36% to 40% reduction: Atorvastatin 20 mg or rosuvastatin 5 mg
- 41% to 50% reduction: Atorvastatin 40+ mg or rosuvastatin 10 mg
- 51% to 55% reduction: Atorvastatin 80 mg or rosuvastatin 20 mg
If you’re switching from one to the other, these equivalencies explain why your new prescription may be a different number of milligrams. A lower number on the label doesn’t mean a weaker dose.
Different Chemistry, Different Behavior in Your Body
One of the most meaningful differences is how these drugs dissolve. Atorvastatin is lipophilic, meaning it dissolves in fat and can easily cross cell membranes throughout your body by passive diffusion. Rosuvastatin is hydrophilic, meaning it dissolves in water and has a harder time entering cells outside the liver.
This distinction has practical consequences. Both drugs are taken up by liver cells, where they do their main job of blocking cholesterol production. But because atorvastatin penetrates other tissues more readily, it can also affect cells in muscle and heart tissue. Lipophilic statins like atorvastatin have been shown to reduce levels of coenzyme Q10 and cellular energy stores in heart muscle, something hydrophilic statins like rosuvastatin are less likely to do. Whether that translates into a noticeable difference for most people is still debated, but for patients with kidney problems or other risk factors, the distinction can influence which statin a prescriber chooses.
Drug Interactions Are Notably Different
This is where the two drugs diverge most sharply. Atorvastatin is broken down by a liver enzyme called CYP3A4, one of the busiest drug-processing pathways in your body. Dozens of common medications also use or block this same pathway, which means taking them alongside atorvastatin can cause its levels to build up in your blood, raising the risk of side effects like muscle damage.
Medications that can interfere with atorvastatin include certain antibiotics (erythromycin, clarithromycin), antifungals (itraconazole, ketoconazole), heart rhythm drugs like amiodarone, calcium channel blockers like verapamil and diltiazem, and even the supplement St. John’s Wort. The blood pressure medication amlodipine, which is frequently prescribed alongside statins, is also a moderate inhibitor of this pathway.
Rosuvastatin largely sidesteps this problem. It is not significantly processed by CYP3A4, so the long list of interacting drugs above is mostly irrelevant to rosuvastatin users. It is metabolized to a minor extent by a different enzyme (CYP2C9), but this pathway is far less prone to clinically significant interactions. If you take multiple medications, this difference alone can be a deciding factor.
Side Effects Are Similar but Not Identical
As a class, statins slightly increase the odds of developing diabetes (about 9% higher than placebo across large studies) and can elevate liver enzymes. These risks apply to both atorvastatin and rosuvastatin.
Muscle pain is the side effect people worry about most, but large meta-analyses have found that individual statins, including both of these, don’t cause significantly more muscle pain than a placebo in controlled trials. That said, perceived muscle symptoms remain a common reason people stop taking statins, and higher doses of both atorvastatin and rosuvastatin are associated with higher rates of people discontinuing treatment. Higher doses of atorvastatin are also linked to greater odds of liver enzyme elevations specifically, a finding that wasn’t as pronounced with rosuvastatin in the same analysis.
Dosing Timing and Half-Life
Rosuvastatin has a plasma half-life of about 19 hours, while atorvastatin’s is around 15 hours. Both are long enough that you can take either drug at whatever time of day works best for you. Shorter-acting statins like simvastatin need to be taken at bedtime because cholesterol production peaks overnight, but atorvastatin and rosuvastatin stay active long enough that timing is flexible.
Kidney Disease Changes the Equation
If you have reduced kidney function, rosuvastatin requires dose adjustments that atorvastatin does not. For people with severe kidney impairment (a creatinine clearance below 30), the FDA recommends starting rosuvastatin at 5 mg and capping it at 10 mg daily. Mild or moderate kidney impairment doesn’t require rosuvastatin dose changes, and atorvastatin generally doesn’t need renal dose adjustments at all. For patients with significant kidney disease, this is a meaningful practical difference between the two drugs.
Long-Term Outcomes Are Comparable
Despite their pharmacological differences, the two drugs produce very similar results where it counts most: keeping people alive and free of heart attacks and strokes. The LODESTAR trial, a large randomized study in patients with coronary artery disease, found that the rate of death, stroke, heart attack, or need for a repeat heart procedure at three years was 8.7% in the rosuvastatin group versus 8.2% in the atorvastatin group, a difference that was not statistically significant.
In short, these are two distinct medications that accomplish the same goal through slightly different paths. Rosuvastatin is more potent per milligram, has fewer drug interactions, and needs dose adjustments in severe kidney disease. Atorvastatin has a longer track record, wider tissue penetration, and more interaction risk with common medications. For most people, either one will effectively lower cholesterol and reduce cardiovascular risk. The choice between them typically comes down to what other medications you take, how your kidneys are functioning, and how your body tolerates each drug individually.